Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Transfer of Energy Capacitive and Resistive Therapy on Shoulder Range of Motion In Idiopathic Adhesive Capsulitis

NCT07788287 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-09
Last updated
2026-08-26

Condition(s) studied

Adhesive Capsulitis

Investigational drug(s) / intervention(s)

Transfer of Energy Capacitive and Resistive (TECAR) TherapyStretching exercises

Transfer of Energy Capacitive and Resistive (TECAR) Therapy: To apply TECAR therapy, the patient will lie supine, with the passive electrode, a flexible rectangular stainless steel plate measuring 150 £ 200 mm, placed under the affected side's scapula. A rigid circular metallic electrode with a 60-mm diameter will be used as the active electrode. Using the resistive mode with the power of 8 to 10 mA, the active electrode will be circularly moved continuously for 10 minutes on the anterior-inferior shoulder capsule while the patient's arm will be held at the end existing range of abduction and external rotation. As well, a conductive cream will be used as a coupling medium between the electrodes and the skin. Based on the manufacturer's recommendation for safe performance, the TECAR intensity will be set as the most effective method, causing no pain based on each patient's feedback.

Stretching exercises: While the patients were lying on the bed, they would receive cyclic (intermittent) stretching. Cyclic stretching is the application, release, and reapplication of a relatively short-duration stretch force repeatedly but progressively. Twenty seconds of stretching and 10 seconds of rest will be used 10 times in each of the following directions (flexion, scapular plane abduction, external rotation, and internal rotation) and stretch to target rotator cuff interval.

Study summary

The current study's general aim is to compare the effectiveness of Transfer of Energy Capacitive and Resistive (TECAR) therapy combined with stretching versus stretching alone in patients with adhesive capsulitis stage 2,3 on range of motion, pain, and function.

Eligibility

Sex
ALL
Min age
40 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Patients of both genders with primary adhesive capsulitis. * Patients aged between 40-65. * Pain duration of three months or more. * Range of motion loss of greater than 25% in at least 2 planes and passive external rotation loss that is greater than 50% of the uninvolved shoulder or less than 30° of external rotation. Exclusion Criteria: * Bilateral adhesive capsulitis, * Systemic diseases such as rheumatoid arthritis, * Malignancies, * Heart diseases * Infections * Coagulation disorders * Full rotator cuff tear * History of recent shoulder surgery * Neurological problems involving the upper extremity * Shoulder joint osteoarthritis * Upper extremity fractures * Cervical radiculopathy * Impaired sensation * Having a heart pacemaker * Pregnancy * Physiotherapy treatment in the previous 6 weeks

Primary outcome measure(s)

  • Glenohumeral External Rotation range of motion (ROM) in Adducted shoulder — 1 month
    To measure external rotation range of motion (ROM) with the shoulder adducted, the patient will be positioned in supine with the upper arm positioned at the side and the elbow flexed to 90°. The examiner will passively externally rotate the glenohumeral joint until end range is reached. Range of motion will be measured by placing the axis of the goniometer on the olecranon process. The stationary arm will be aligned with the vertical position. The movable arm will be aligned with the ulnar styloid process.
  • Glenohumeral External Rotation range of motion (ROM) in Abducted shoulder — 1 month
    External rotation range of motion (ROM) may also be measured with the shoulder abducted to 45° or to 90° in the frontal plane (if the patient has the available abduction ROM). The stationary arm of goniometer will be aligned with the vertical position. The movable arm will be aligned with the ulnar styloid process.
  • Glenohumeral Internal Rotation range of motion (ROM) in Abducted shoulder — 1 month
    Internal rotation range of motion (ROM) will be measured while the patient is positioned in supine, the shoulder abducted to 90°, and the elbow flexed to 90°. If glenohumeral abduction is less than 90°, a 45° abduction angle can be used. The examiner passively internally rotates the glenohumeral joint until end range is reached, ensuring that there is no scapular compensation. Range of motion will be measured by placing the axis of the goniometer on the olecranon process. The stationary arm will be aligned with the vertical position. The movable arm will be aligned with the ulnar styloid process
  • Shoulder Flexion range of motion (ROM) — 1 month
    To measure flexion range of motion (ROM), the patient will be positioned in supine with the arm rest at the side. The examiner will passively flex the shoulder until end range is reached (with no compensatory movements from the thorax and the lumbar spine). Range of motion will be measured by placing the axis of the goniometer on the greater tuberosity. The stationary arm will be aligned with the midline of the trunk. The movable arm will be aligned with the lateral epicondyle.
  • Shoulder Abduction range of motion (ROM) — 1 month
    To measure abduction range of motion (ROM), the patient will be positioned in supine with the arm comfortably by the side. The examiner passively abducts the shoulder until end range is reached (shoulder must remain in the same plane). Range of motion will be measured by placing the axis of the goniometer on the head of the humerus. The stationary arm will be aligned parallel with the midline of the sternum. The movable arm will be aligned with the midshaft of the humerus.
  • Shoulder extension range of motion (ROM) — 1 month
    To measure extension range of motion (ROM), the patient is positioned in prone position with the arm rest at the side. The examiner passively extends the shoulder until the end range is reached. Range of motion will be measured by placing the axis of the goniometer on the greater tuberosity. The stationary arm will be aligned with the midline of the trunk. The movable arm will be aligned with the lateral epicondyle.

Trial sites (1)

FacilityCityRegionStatus
Cairo university Cairo Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07788287 on ClinicalTrials.gov ↗ ← All trials in Egypt